U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H17FN3O4.K
Molecular Weight 409.4527
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GSK-364735 POTASSIUM

SMILES

[K+].CN1C(=O)C(C(=O)NCCO)=C([O-])C2=NC=C(CC3=CC=C(F)C=C3)C=C12

InChI

InChIKey=KHOKPZJZSBGEPY-UHFFFAOYSA-M
InChI=1S/C19H18FN3O4.K/c1-23-14-9-12(8-11-2-4-13(20)5-3-11)10-22-16(14)17(25)15(19(23)27)18(26)21-6-7-24;/h2-5,9-10,24-25H,6-8H2,1H3,(H,21,26);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C19H17FN3O4
Molecular Weight 370.3544
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

GlaxoSmithKline was developing GSK-364735 as a human immunodeficiency virus (HIV) integrase inhibitor. The inhibition of viral DNA integration takes place by interacting at the two-metal binding site within the catalytic center of HIV integrase. GSK-364735 was successfully studied at Phase II in HIV-infected patients; however, adverse liver effects of GSK364735 were recently observed in a long-term preclinical safety study in the monkey and preclude further development of the compound.

Approval Year

PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

In part A, three alternating cohorts of 10 subjects (8 receiving the active drug and 2 receiving a placebo) received single doses of 50 to 400 mg while fasting or 200 mg and 400 mg coadministered with food. In part B, five cohorts received repeated doses of 100 to 600 mg daily coadministered with food for 8 days.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:31:55 GMT 2023
Edited
by admin
on Sat Dec 16 11:31:55 GMT 2023
Record UNII
324268A537
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GSK-364735 POTASSIUM
Common Name English
1,5-NAPHTHYRIDINE-3-CARBOXAMIDE, 7-((4-FLUOROPHENYL)METHYL)-1,2-DIHYDRO-4-HYDROXY-N-(2-HYDROXYETHYL)-1-METHYL-2-OXO-, POTASSIUM SALT (1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
119025700
Created by admin on Sat Dec 16 11:31:55 GMT 2023 , Edited by admin on Sat Dec 16 11:31:55 GMT 2023
PRIMARY
FDA UNII
324268A537
Created by admin on Sat Dec 16 11:31:55 GMT 2023 , Edited by admin on Sat Dec 16 11:31:55 GMT 2023
PRIMARY
CAS
912672-93-6
Created by admin on Sat Dec 16 11:31:55 GMT 2023 , Edited by admin on Sat Dec 16 11:31:55 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY